Urodynamix Announces Annual and Special Shareholder Meeting Agenda

VANCOUVER, British Columbia, May 4, 2007 - Urodynamix Technologies Ltd. (TSX-V:URO) announced that it will hold its 2007 Annual and Special Meeting (the “Meeting”) in Vancouver, British Columbia on June 4, 2007.

The Company is pleased to announce the addition of Pierre Leduc to the proposed slate of directors. Mr. Leduc is principal of Leduc Associates Management Consultants, a firm specializing in biotechnology companies. Prior to forming his consultancy, he served as President and CEO of Neurostream Technologies Inc., a privately held medical device company developing implantable neurotechnology devices. Mr. Leduc was also Chairman of Xillix Technologies Corp., a TSX-listed medical device company engaged in the manufacture of endoscopic devices for the early detection of cancer. Earlier in his career, Mr. Leduc had a 20-year association with Baxter Corporation in many executive capacities, including President of Baxter Corporation Canada, Area Managing Director, Australia-New Zealand and Marketing Manager, Americas-Pacific, Baxter World Trade Corp., Deerfield, Illinois. Mr. Leduc currently serves on the Board of Directors of Providence Health Care and Ondine Biopharma Inc. of Vancouver, BC and Novx Systems Inc. of Markham, Ontario.

“Urodynamix is very pleased to have Mr. Leduc join the Board of Directors. His experience growing public and private biotechnology companies as well as his long history at Baxter Corporation will add a welcome perspective to the Board,” said Barry Allen, Chairman of the Board of Urodynamix. “We would like to thank Mr. Blair for his contributions to the Board and the growth of the Company.”

In order to appeal to certain investors that find shares trading at above certain prices more attractive from an investment perspective, the Company is proposing that its Board of Directors be given discretionary authority at the Meeting to effect a share consolidation. A share consolidation may have the effect of raising the market price of the Company’s shares but does not have an effect on the actual or intrinsic value of the business of the Company or on a shareholder’s proportional ownership in the Company.

Shareholders will be asked to vote on a special resolution at the Meeting authorizing the Board of Directors, if and when it deems appropriate, but prior to June 4, 2008, to consolidate the then outstanding common shares of the Company within a range of one new common share for two outstanding common shares and one new common share for ten outstanding common shares as it shall, in its discretion, determine. The Board would also have the discretion not to effect the share consolidation.

The share consolidation is subject to shareholder approval and to TSX Venture Exchange acceptance. No name change will occur in conjunction with the consolidation.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urinary incontinence in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company’s disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

“Barry Allen”
President & CEO
Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Craig Pamplin, PhD, CFA

Director, Corporate Development and Communications

Urodynamix Technologies Ltd.

Tel: (604) 638-0247

Email: cpamplin@urodynamix.com